Original Article

Chronic Lymphocytic Leukemia in Turkey: Experience of a Single Center in Istanbul

Authors: Ömer Nuri Pamuk, MD, Gülsüm Emel Pamuk, MD, Teoman Soysal, MD, Şeniz Öngören, MD, Zafer Başlar, MD, Burhan Ferhanoğlu, MD, Yildiz Aydin MD, Birsen Ülkü, MD, Gulten Aktuğlu, MD, Nuran Akman MD

Abstract

Background: In this study, the clinical characteristics, survival, and prognostic factors of 200 patients diagnosed as having chronic lymphocytic leukemia (CLL) were analyzed.


Methods: The medical charts of 200 CLL patients registered to our center between 1984 and 2000 were retrospectively evaluated.


Results: Of all patients, 129 were men and 71 were women (male/female ratio, 1.82). The median age at the time of initial diagnosis was 63 years (range, 38–90 years). Sixty patients were classified as Binet’s Stage A, 49 as Stage B, and 91 as Stage C. Sixty-two cases were diagnosed during routine laboratory examinations when they were asymptomatic. Forty-three patients were lost to follow-up, and 157 patients have been followed regularly until the end of the study period. Hemolytic anemia developed in nine (5.7%) patients, second primary cancer in six (3.8%), and Richter’s syndrome in two (1.2%). Forty-eight percent of CLL patients were treated immediately after initial diagnosis. The overall response (complete or partial) to first-line and second-line therapies was 61.6% and 54.4%, respectively. The median time of follow-up for patients followed up regularly was 47 months (range, 1–195 months). Sixty-three patients died during the follow-up: the deaths of 39 (62%) of these were attributable to CLL-related causes. The median survival time was 48 months. The 5-year survival rate was 36.5% and the 10-year survival rate was 8%. Stage according to Rai’s classification, lymphocyte count, and age showed a significant prognostic effect on survival by univariate analysis. On multivariate analysis, advanced age and lymphocyte count were independent prognostic parameters.


Conclusion: In our study, more asymptomatic CLL patients have been diagnosed in recent years. The survival, especially of our early-stage patients, was shorter than that in other CLL series of Western origin. Rai’s staging system was seen to determine prognosis better than Binet’s staging system.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057.
 
2. Keating MJ. Chronic lymphocytic leukemia, in Henderson ES, Lister TA, Greaves MF (eds): Leukemia. Philadelphia, W.B. Saunders Co., 1996, pp 554–586.
 
3. Call TG, Phyliky RL, Noel P. Incidence of chronic lymphocytic leukemia in Olmstead Country, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 323–328.
 
4. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.
 
5. French Cooperative Group on Chronic Lymphocytic Leukemia. Comparison of the (A, B, C) staging and the Rai’s staging from a large prospective series (935 patients). Nouv Rev Fr Hematol 1988; 30: 363–367.
 
6. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: Staging and prognostic factors. Semin Oncol 1998; 25: 42–49.
 
7. Criel A, Verhoef G, Vlietinck R, et al. Further characterization of morphologically defined typical and atypical CLL: A clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997; 97: 383–391.
 
8. Hallek M, Kuhn-Hallek I, Emmerich B. Prognostic factors in chronic lymphocytic leukemia. Leukemia 1997; 11 (Suppl 2): S4–S13.
 
9. International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110: 236–238.
 
10. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.
 
11. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern: The best single prognostic parameter in chronic lymphocytic leukemia—a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.
 
12. Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.
 
13. de Lima M, O’Brien S, Lerner S, et al. Chronic lymphocytic leukemia in the young patient. Semin Oncol 1998; 25: 107–116.
 
14. Liner MS, Devesa SS. Descriptive epidemiology of the leukemias, in Henderson ES, Lister TA (eds): Leukemia. Philadelphia, W.B. Saunders Co., 1993, pp 207–225.
 
15. Erlanson M, Osterman B, Jonsson H, et al. Chronic lymphocytic leukemia: A retrospective study of 122 cases. Eur J Haematol 1994; 52: 108–114.
 
16. Rai KR, Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4: 447–456.
 
17. Rozman C, Montserrat E. Newer aspects of prognosis in chronic lymphocytic leukemia. Leukemia 1992; 6 (Suppl 4): 137–139.
 
18. Zengin N, Kars A, Sungur A, et al. The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: A prognostic dilemma. Am J Hematol 1999; 62: 208–211.
 
19. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263.
 
20. Oscier D. Chronic lymphocytic leukemia. Br J Haematol 1999; 105 (Suppl 1): 1–3.
 
21. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999; 94: 448–454.
 
22. Rozman C, Montserrat E, Feliu E, et al. Prognosis of chronic lymphocytic leukemia: A multivariate survival analysis of 150 cases. Blood 1982; 59: 1001–1005.
 
23. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–899.
 
24. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171.
 
25. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.